>>Perceptive Edelman's interview was quite bullish too.
If you agree with his market analysis, we are talking a 10x return if the drug was successful. And I think all will concede this drug had a much better than 10% shot at success in this non-inferiority trial (which generally are easier than a superiority trial). So that made an investment a reasonable idea on a risk/reward basis.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.